• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

Overcoming treatment resistance in acute promyelocytic leukemia and beyond.

作者信息

Fung Tsz Kan, So Chi Wai Eric

出版信息

Oncotarget. 2013 Aug;4(8):1128-9. doi: 10.18632/oncotarget.1244.

DOI:10.18632/oncotarget.1244
PMID:23934744
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC3787144/
Abstract
摘要
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/b51b/3787144/e1743b5e8dc0/oncotarget-04-1128-g001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/b51b/3787144/e1743b5e8dc0/oncotarget-04-1128-g001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/b51b/3787144/e1743b5e8dc0/oncotarget-04-1128-g001.jpg

相似文献

1
Overcoming treatment resistance in acute promyelocytic leukemia and beyond.克服急性早幼粒细胞白血病及其他疾病的治疗耐药性。
Oncotarget. 2013 Aug;4(8):1128-9. doi: 10.18632/oncotarget.1244.
2
Arsenic trioxide-responsive leukemia cutis in a patient with acute promyelocytic leukemia after ATRA treatment.全反式维甲酸治疗后急性早幼粒细胞白血病患者出现的对三氧化二砷有反应的白血病性皮肤浸润
Leuk Lymphoma. 2006 Jul;47(7):1438-40. doi: 10.1080/10428190600612446.
3
Application of heavy metal and cytokine for differentiation-inducing therapy in acute promyelocytic leukemia.重金属和细胞因子在急性早幼粒细胞白血病分化诱导治疗中的应用。
J Natl Cancer Inst. 1998 Dec 16;90(24):1906-7. doi: 10.1093/jnci/90.24.1906.
4
Arsenic and apoptosis in the treatment of acute promyelocytic leukemia.砷与细胞凋亡在急性早幼粒细胞白血病治疗中的作用
J Natl Cancer Inst. 1998 Jan 21;90(2):86-8. doi: 10.1093/jnci/90.2.86.
5
P-glycoprotein (P-gp) and multidrug resistance-associated protein 1 (MRP1) are induced by arsenic trioxide (As(2)O(3)), but are not the main mechanism of As(2)O(3)-resistance in acute promyelocytic leukemia cells.P-糖蛋白（P-gp）和多药耐药相关蛋白1（MRP1）可被三氧化二砷（As₂O₃）诱导，但并非急性早幼粒细胞白血病细胞对As₂O₃耐药的主要机制。
Leukemia. 2003 Mar;17(3):648-50. doi: 10.1038/sj.leu.2402851.
6
Differentiating agents in pediatric malignancies: all-trans-retinoic acid and arsenic in acute promyelocytic leukemia.儿童恶性肿瘤中的分化诱导剂：全反式维甲酸和砷剂在急性早幼粒细胞白血病中的应用
Curr Oncol Rep. 2000 Nov;2(6):519-23. doi: 10.1007/s11912-000-0105-x.
7
[Pharmacological and clinical properties of arsenic trioxide (Trisenox) for relapse or refractory acute promyelocytic leukemia therapy].三氧化二砷（Trisenox）用于复发或难治性急性早幼粒细胞白血病治疗的药理及临床特性
Nihon Yakurigaku Zasshi. 2005 Jun;125(6):389-96. doi: 10.1254/fpj.125.389.
8
Hypoxia-simulating agents selectively stimulate arsenic trioxide-induced growth arrest and cell differentiation in acute promyelocytic leukemic cells.缺氧模拟剂可选择性地刺激三氧化二砷诱导急性早幼粒细胞白血病细胞的生长停滞和细胞分化。
Haematologica. 2005 Dec;90(12):1585A.
9
Arsenic trioxide mechanisms of action--looking beyond acute promyelocytic leukemia.三氧化二砷的作用机制——超越急性早幼粒细胞白血病
Leuk Lymphoma. 2008 Oct;49(10):1846-51. doi: 10.1080/10428190802464745.
10
Treatment of acute promyelocytic leukemia with arsenic trioxide.三氧化二砷治疗急性早幼粒细胞白血病
N Engl J Med. 1999 Apr 1;340(13):1043; author reply 1044-5. doi: 10.1056/NEJM199904013401313.

引用本文的文献

1
Characteristics of doxorubicin-selected multidrug-resistant human leukemia HL-60 cells with tolerance to arsenic trioxide and contribution of leukemia stem cells.阿霉素筛选的对三氧化二砷耐受的多药耐药人白血病HL-60细胞的特征及白血病干细胞的作用
Oncol Lett. 2018 Jan;15(1):1255-1262. doi: 10.3892/ol.2017.7353. Epub 2017 Nov 6.
2
HA117 endows HL60 cells with a stem-like signature by inhibiting the degradation of DNMT1 via its ability to down-regulate expression of the GGL domain of RGS6.HA117通过下调RGS6的GGL结构域表达，抑制DNMT1的降解，赋予HL60细胞一种干细胞样特征。
PLoS One. 2017 Jun 30;12(6):e0180142. doi: 10.1371/journal.pone.0180142. eCollection 2017.
3
Phenylarsine Oxide Can Induce the Arsenite-Resistance Mutant PML Protein Solubility Changes.
苯胂化氧可诱导抗亚砷酸盐突变型早幼粒细胞白血病（PML）蛋白的溶解性变化。
Int J Mol Sci. 2017 Jan 25;18(2):247. doi: 10.3390/ijms18020247.
4
Epigenetic therapies by targeting aberrant histone methylome in AML: molecular mechanisms, current preclinical and clinical development.通过靶向急性髓系白血病中异常组蛋白甲基化组的表观遗传疗法：分子机制、当前临床前和临床进展
Oncogene. 2017 Mar 30;36(13):1753-1759. doi: 10.1038/onc.2016.315. Epub 2016 Sep 5.
5
Targeting Aberrant Epigenetic Networks Mediated by PRMT1 and KDM4C in Acute Myeloid Leukemia.靶向PRMT1和KDM4C介导的急性髓系白血病异常表观遗传网络
Cancer Cell. 2016 Jan 11;29(1):32-48. doi: 10.1016/j.ccell.2015.12.007.
6
Nanotechnology applications in hematological malignancies (Review).纳米技术在血液系统恶性肿瘤中的应用（综述）
Oncol Rep. 2015 Sep;34(3):1097-105. doi: 10.3892/or.2015.4100. Epub 2015 Jul 2.
7
Critical role of retinoid/rexinoid signaling in mediating transformation and therapeutic response of NUP98-RARG leukemia.维甲酸/类视黄醇信号在介导 NUP98-RARG 白血病的转化和治疗反应中的关键作用。
Leukemia. 2015 May;29(5):1153-62. doi: 10.1038/leu.2014.334. Epub 2014 Dec 16.
8
New strategies in acute promyelocytic leukemia: moving to an entirely oral, chemotherapy-free upfront management approach.急性早幼粒细胞白血病的新策略：转向完全口服、无化疗的初始治疗方法。
Clin Cancer Res. 2014 Oct 1;20(19):4985-93. doi: 10.1158/1078-0432.CCR-13-2725.
9
Epigenetics in acute promyelocytic leukaemia pathogenesis and treatment response: a TRAnsition to targeted therapies.表观遗传学在急性早幼粒细胞白血病发病机制及治疗反应中的作用：向靶向治疗的转变
Br J Cancer. 2015 Feb 3;112(3):413-8. doi: 10.1038/bjc.2014.374. Epub 2014 Sep 23.
10
DNA damage accumulation and repair defects in acute myeloid leukemia: implications for pathogenesis, disease progression, and chemotherapy resistance.急性髓系白血病中的DNA损伤积累与修复缺陷：对发病机制、疾病进展及化疗耐药性的影响
Chromosoma. 2014 Dec;123(6):545-61. doi: 10.1007/s00412-014-0482-9. Epub 2014 Aug 12.